Darah Protas

Associate
Full contact info

Experience

Immunology Company argenx Announces $1.27 Billion Global Offering

July 26, 2023

Cooley advised J.P. Morgan, Morgan Stanley, Goldman Sachs, BofA Securities and TD Cowen, representatives of the several underwriters, in the $1.27 billion follow-on offering by argenx SE, a global immunology company.

Read more

Related contacts

Richard Segal
Partner, New York
Div Gupta
Partner, New York
Darah Protas
Associate, Washington DC
Charles York
Associate, New York
Katie Lapidus
Associate, Washington DC
Carley Cruea
Associate, Washington DC
Bill Christiansen
Partner, Seattle
Phil Mitchell
Partner, New York
Natasha Leskovsek
Of Counsel, Washington DC
Jennifer Shanley
Special Counsel, New York
Dr. Tian Yong Zheng
Patent Agent, Seattle

Related Practices & Industries

Apogee Therapeutics Announces Upsized $345.1 Million IPO

July 18, 2023

Cooley advised the underwriters in the upsized $345.1 million initial public offering of Apogee Therapeutics, a biotechnology company.

Read more

Related contacts

Charlie Kim
Partner, San Diego
Div Gupta
Partner, New York
Kristin VanderPas
Partner, San Francisco
Madhuri Roy
Partner, Palo Alto
Stephanie Gentile
Partner, New York
Geoffrey Spolyar
Partner, Boston
Phil Mitchell
Partner, New York
Francis Wheeler
Partner, Colorado
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Randy Sabett
Special Counsel, Washington DC
Natasha Leskovsek
Of Counsel, Washington DC
Rebecca Ross
Special Counsel, Washington DC
Jennifer Shanley
Special Counsel, New York
Madison (JJ) Meng
Associate, San Francisco
Megan Drill
Associate, San Diego
Alessandra Murata
Partner, Palo Alto
Darah Protas
Associate, Washington DC
Mike Lam
Associate, Los Angeles Santa Monica
David Dalton
Associate, Los Angeles Santa Monica
Peter A. Haddad
Associate, San Diego

Related Practices & Industries

Prelude Therapeutics – $100 Million Follow-on Offering

May 18, 2023

Cooley advised the underwriters in Prelude Therapeutics’ $100 million follow-on offering. Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. Lawyers Richard Segal, Div Gupta, Darah Protas, Sam Paullin and Katie Lapidus led the Cooley team.

Related contacts

Richard Segal
Partner, New York
Virat Gupta
Associate, Washington DC
Darah Protas
Associate, Washington DC
Samuel Paullin
Associate, Chicago
Katie Lapidus
Associate, Washington DC

Related Practices & Industries

Karuna Therapeutics – $862.5 Million Follow-on Offering

September 7, 2022

Cooley advised the underwriters in Karuna Therapeutics’ $862.5 million follow-on offering of 4,011,628 shares of common stock at a public offering price of $215 per share. Karuna is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions. Partners Richard Segal, Jean Park, Div Gupta and associate Darah Protas led the Cooley team.

Related contacts

Richard Segal
Partner, New York
Jean Park
Partner, New York
Div Gupta
Partner, New York
Darah Protas
Associate, Washington DC
Charles York
Associate, New York
Katie Lapidus
Associate, Washington DC
Quay Strozier
Associate, Washington DC
Katherine King
Associate, Washington DC

Related Practices & Industries

Verve Therapeutics – $258.8 Million Follow-on Offering

August 26, 2022

Cooley advised the underwriters in Verve Therapeutics’ $258.8 million follow-on offering of 9,583,334 shares of common stock at a public offering price of $27 per share. Verve is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, potentially transforming treatment from chronic management to single-course gene-editing medicines. Partners Rich Segal and Div Gupta, and associate Darah Protas, led the Cooley team.

Related contacts

Richard Segal
Partner, New York
Div Gupta
Partner, New York
Darah Protas
Associate, Washington DC
Kindall G. Jackson
Associate, Washington DC

Related Practices & Industries

View more